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BACKGROUND: More than one-third of the estimated 2
million prostate cancer survivors in the United States
receive androgen deprivation therapy (ADT). This pop-
ulation of mostly older men is medically vulnerable to a
variety of treatment-associated adverse effects.
MEASUREMENTSANDRESULTS:Androgen-deprivation
therapy (ADT) causes loss of libido, vasomotor flushing,
anemia, and fatigue. More recently, ADT has been shown
to accelerate bone loss, increase fat mass, increase
cholesterol and triglycerides, and decrease insulin sensi-
tivity. Consistent with these adverse metabolic effects,
ADT has also recently been associated with greater risks
for fractures, diabetes and cardiovascular disease.
CONCLUSION: Primary care clinicians and patients
should be aware of the potential benefits and harms of
ADT. Screening and intervention to prevent treatment-
related morbidity should be incorporated into the routine
care of prostate cancer survivors. Evidence-based guide-
lines to prevent fractures, diabetes, and cardiovascular
diseasein prostatecancer survivors represent animportant
unmet need. We recommend the adapted use of established
practice guidelines designed for the general population.
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SCOPE OF THE PROBLEM
Prostate cancer is the most common malignancy in men. The
median age at diagnosis of prostate cancer is 68 years.
1 Prostate
cancer does not alter life expectancy for most of these men as
the 5-year relative survival for all stages combined is 98.8%.
1
Even those who present with metastatic disease have a median
survival of approximately 30 months
2,3 and a 10-year survival
approaching 10%.
4 With improvements in cancer-specific sur-
vival, treatment-related morbidity has become more relevant to
the long-term health of prostate cancer survivors.
Androgens can stimulate prostate cancer growth. Lowering
androgen levels with androgen deprivation therapy (ADT) is the
primary systemic treatment for prostate cancer. ADT is
accomplished by either bilateral orchiectomies or medical
castration with a gonadotropin-releasing hormone (GnRH)
agonist. ADT achieves objective responses in over 80% of those
treated.
5,6 Most men are treated with a GnRH agonist rather
than bilateral orchiectomies as GnRH agonists are easily
administered, reversible, and more acceptable to patients.
GnRH agonist use has risen markedly over the last 2 decades
across all ages, disease stages and tumor grades.
7,8 Currently,
more than one-third of the estimated 2 million prostate cancer
survivors in the United States are treated with GnRH agonists.
9
ADT is the central treatment for metastatic prostate cancer
as it improves bone pain, modestly prolongs overall survival
and produces some 10-year survivors.
10 GnRH agonists have
been shown to improve disease-free and overall survival in
combination with radiation for locally advanced or high-risk
nonmetastatic disease.
11,12 Adjuvant therapy with a GnRH
agonist also improves survival in men with node-positive
disease after radical prostatectomy.
13
ADT is also used for settings where evidence of benefit is less
clear. PSA monitoring after primary therapy often detects
recurrences long before symptoms or imaging would have
revealed them. A rising PSA after primary surgery or radiation
therapy commonly leads to long-term ADT, although the effects
of early ADT for “PSA-only” recurrences on mortality have not
been adequately characterized.
14 Additionally, some men with
localized disease opt for long-term ADT instead of radiation or
surgery, a practice that has not been shown to improve
survival relative to observation.
15
The therapeutic effect of ADT is severe hypogonadism.
GnRH agonists lead to a striking reduction in serum testos-
terone and a number of physiologic changes. Adverse changes
in bone mineral density, body composition, lipid profile and
insulin sensitivity are among the effects of GnRH agonist
therapy. Men receiving GnRH agonists experience elevated
risks for fracture,
16 diabetes and cardiovascular disease,
9 all of
which cause substantial morbidity to elderly men at baseline.
With the introduction of PSA screening, fewer than 5% of
men have detectable metastases at presentation.
17 Earlier
diagnosis and more aggressive interventions have increased
the burden of treatment for prostate cancer survivors.
Here we provide a focused review of the recently recognized
complications of ADT: osteoporosis and fractures, obesity and
sarcopenia, insulin resistance and diabetes, and cardiovascular
disease. Readers are referred elsewhere for systematic reviews
about these and other adverse effects of ADT.
18,19 We also provide
our recommendations for prevention and treatment of fractures,
diabetes and cardiovascular disease in men treated with ADT. Our
recommendations, detailed in Table 1, are adapted from broadly
accepted practice guidelines from the National Osteoporosis
Foundation (NOF), the American Diabetes Association (ADA), the
S389National Cholesterol Education Program Adult Treatment Panel
III (NCEPATP III) and the American Heart Association (AHA).
Evidence-based guidelines for men on ADT are lacking. This
is due in part to the fact that these ADT-specific hazards were
identified relatively recently and are still being fully defined.
Moreover, few studies of various strategies to screen for and/or
manage prostate cancer patients on ADT have been completed
to date. Further clinical investigation is needed to better define
the most effective strategies to promote health among prostate
cancer survivors.
OSTEOPOROSIS AND FRACTURES
Fractures cause significant morbidity in men worldwide.
20
One in three hip fractures occur in men.
21 Hypogonadism,
chronic glucocorticoid therapy and alcohol abuse are the
most common causes of acquired osteoporosis in men.
22
ADT accelerates bone turnover
23,24, decreases bone mineral
density
23–28 and contributes to fracture risk.
16,29,30 Analysis in
the Surveillance, Epidemiology and End Results (SEER)
Medicare database of over 50,000 older men with prostate
cancer revealed that among those surviving 5 years beyond
diagnosis, fracture rates were 19.4% in men who received ADT
and 12.6% in men who did not.
16 A second claims-based
analysis in men with nonmetastatic prostate cancer similarly
showed a significant association between GnRH agonist use
and fractures (RR 1.21; P<0.001).
29
Bisphosphonates including pamidronate,
31,32 zoledronic
acid
33,34 and alendronate
35 have been shown to improve bone
mineral density and decrease markers of bone metabolism in
men on ADT. Notably, none of the completed studies was
designed to prevent fracture.
Selective Estrogen Receptor Modulators (SERMs) have been
tested for their effects on bone mineral density and markers of
bone metabolism in men receiving ADT. Raloxifene
36 and
toremifene
37 are both SERMs that increase bone mineral
density and decrease markers of bone metabolism in men
treated with ADT. Recently, toremifene has been evaluated in a
multicenter phase III study powered to demonstrate fracture
prevention (see Table 2). The trial enrolled 1,389 men with low
bone mineral density and/or age ≥70 and randomized them to
receive daily toremifene or placebo for 24 months. In a
preliminary report, toremifene significantly decreased new
vertebral fractures and increased bone mineral density at all
measured skeletal sites.
38
Receptor activator of nuclear factor-kappa-B ligand (RANKL)
is a critical regulator of osteoclast differentiation, function and
survival.
39–43 Denosumab is a subcutaneously administered
fully human monoclonal antibody against RANKL. It is in
broad clinical development for postmenopausal osteoporosis,
osteoporosis in cancer survivors and the prevention and
treatment of bone metastases. Denosumab has been studied
in a randomized, placebo-controlled fracture prevention trial
that enrolled over 1,400 men at high risk for fracture due to
ongoing ADT, older age and/or low bone mineral density (see
Table 2). The study was completed in 2008; final results are
pending.
Accurate assessment of fracture risk is necessary to identify
which men are most likely to benefit from treatment. The World
Health Organization/FRAX model improves fracture risk
Table 1. Recommendations for Men Receiving ADT for Prostate
Cancer*
Osteoporosis
Screening: BMD testing for all men on ADT given the NOF
recommendation for adults receiving a medicine associated with
bone loss; test at baseline, repeat after 1 year of ADT, then repeat
every 2 years or as clinically indicated
Treatment: Supplemental calcium (≥1,200 mg daily) and vitamin D
(800–1,000 IU daily) for all and consideration of drug treatment if age
≥50 and any of:
• Personal history of hip or vertebral fracture
• T-score ≤−2.5 at the femoral neck or spine (secondary causes evaluated)
• Low T-score at femoral neck or spine (−1.0 to −2.5) and by US-adapted
WHO algorithm:
- 10-year probability of a hip fracture ≥3% or
- 10-year probability of a major osteoporosis-related fracture ≥20%
Diabetes and pre-diabetes
Screening:
• Consider testing in all men treated with ADT at baseline and yearly
thereafter while receiving ADT
• Recommended test: fasting plasma glucose (FPG)
• Impaired Fasting Glucose (IFG) = FPG 100–125 mg/dl
• The use of hemoglobin A1C for the diagnosis of diabetes is not
recommended
Treatment of pre-diabetes/IFG:
• For those identified with pre-diabetes, treat other CHD risk factors
• For those diagnosed with pre-diabetes, repeat testing at least yearly
and counsel lifestyle interventions (with follow-up counseling):
• 5–10% weight loss
• ≥150 min/week of moderate physical activity
Hyperlipidemia and CHD risk factors
Screening:
• Fasting lipoproteins at baseline, within 1 year of ADT initiation, then
every 5 years or as clinically indicated
• Assign target LDL based on major CHD risk factors as outlined in
NCEP ATP III
Treatment:
• Emphasis on primary prevention
• Tobacco cessation for all
• Treatment of hypertension per AHA guidelines
• Lifestyle interventions:
• Reduce intake of saturated fat and cholesterol
• Increase physical activity
• Weight control
• Low-dose aspirin in men with 10-year CHD risk ≥10%
• Statins are first line for hyperlipidemia if lifestyle fails to meet target LDL
Key: ADT, androgen deprivation therapy; BMD, bone mineral density;
LDL low density lipoprotein; CHD, coronary heart disease; FPG, fasting
plasma glucose; IFG, impaired fasting glucose
*Our recommendations are adapted for the clinical situation from practice
guidelines published by the National Osteoporosis Foundation (NOF), the
American Diabetes Association (ADA), the National Cholesterol Education
Program Adult Treatment Panel III (NCEPATP III) and the American Heart
Association (AHA)
Table 2. Completed Phase III Fracture Prevention Trials
Study drug N Population Arms Endpoint(s)
Denosumab
(RANK-L
inhibitor)
>1,400 Current ADT,
high risk
due to old
age and/or
low BMD
Denosumab
vs. placebo
New vertebral
fractures, bone
mineral density
Toremifene
(SERM)
1,392 Current
ADT, ≥50
years old
Toremifene
vs. placebo
Incident vertebral
fractures within
24 months, bone
mineral density,
lipid profile
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addition to femoral neck bone mineral density (http://www.
shef.ac.uk/FRAX/index.htm).
44–46 These clinical risk factors
are based on large meta-analyses and include prior fragility
f r a c t u r e ,f a m i l yh i s t o r yo fh i pf r a c t u r e ,c u r r e n tt o b a c c o
smoking, chronic use of glucocorticoids, daily consumption of
alcohol, rheumatoid arthritis and other conditions associated
with secondary osteoporosis.
41–54 Men receiving GnRH ago-
nists are a high-risk population and should be screened for
fracture risk with bone mineral density testing at baseline,
after 1 year of ADT, then every 2 years or as clinically indicated
(see Table 1).
The 2008 NOF guidelines recommend calcium (≥1,200 mg
daily) and vitamin D (800–1,000 IU daily) supplementation for
all men age 50 or over. The guidelines also recommend drug
therapy for those who have low T-score (−1.0 to −2.5) at the
femoral neck or spine and 10-year risk of at least 3% for hip
fracture or at least 20% for any osteoporosis-related fracture
according to the US-adapted FRAX model.
55 We believe that
existing data clearly support considering ADT as a cause of
secondary osteoporosis when using the FRAX tool. Although
the ability of pharmacologic therapy to prevent fracture among
men on ADT remains preliminary, the results of two phase III
fracture prevention trials are anticipated soon.
OBESITY AND SARCOPENIA
Approximately one in three American men are obese [body
mass index (BMI) ≥30.0 kg/m
2].
56 Androgens are important
determinants of body composition as they promote lean body
mass over fat mass.
57 Conversely, ADT increases fat mass and
decreases lean body mass.
25,58
Prospective clinical trials have shown that 1 year of ADT
causes approximately a 10% increase in fat body mass, a 3%
fall in lean body mass and 2% increase in overall weight.
58–60
Cross-sectional imaging has revealed that abdominal girth
increases during GnRH agonist therapy because of subcuta-
neous rather than intra-abdominal fat.
58,61 Abdominal adi-
posity is a particular concern, as a very large prospective
European cohort study found that waist circumference was
strongly associated with risk of death even after adjustment for
BMI.
62 ADT-associated changes in body composition occur
early in treatment, with significant rises in fat body mass
63 as
well as accompanying increases in plasma insulin
63,64 occur-
ring within 3 months of GnRH agonist therapy.
The optimal strategy to prevent or reverse these adverse
changes in body composition during GnRH therapy is un-
known. One study randomized 155 men to three-times-per-
week resistance exercise or to a waiting list control group and
found no difference in body composition between the groups at
3 months.
65 Resistance training did provide some benefit in
the form of less fatigue, higher quality of life and higher levels
of muscular fitness. Further research on the treatment and
prevention of ADT-associated changes in body composition is
needed.
LIPID ALTERATIONS
GnRH agonists cause increases in total cholesterol (approxi-
mately 10%), triglycerides (approximately 26%) and high-
density lipoprotein (HDL) (approximately 8–11%),
58,66,67 and
these changes have been observed after just 3 months of
therapy.
63,66 Clinician awareness of the potential for these
changes can facilitate appropriate monitoring and manage-
ment. We recommend fasting lipoproteins at baseline, within 1
year of ADT initiation and as clinically indicated thereafter.
Existing data strongly support a continuous, graded rela-
tionship between serum cholesterol and cardiovascular mor-
tality.
68,69 In the general population, the NCEP ATP-III
guidelines define the standard-of-care.
70 Diet and lifestyle are
first line interventions to achieve target low-density lipoprotein
(LDL). When this is not successful, statins reduce all-cause
mortality and are the first-line pharmacologic intervention.
71
SERMs such as toremifene may benefit men with hyperlip-
idemia during ADT. A recently completed randomized placebo-
controlled phase III trial was designed to primarily evaluate
daily toremifene for fracture prevention in men receiving ADT.
Planned interim analysis at 1 year demonstrated that toremi-
fene decreases LDL cholesterol and triglycerides and increases
HDL cholesterol compared to placebo.
37 The effect of SERMs
on cardiovascular outcomes is not yet known.
INSULIN RESISTANCE
Insulin resistance is associated with obesity and is an
independent risk factor for diabetes and cardiovascular dis-
ease. Its prevalence in the general adult population is about
25%.
72,73 Several small prospective studies have shown that
GnRH agonists increase fasting insulin levels early in the
course of GnRH agonist treatment.
63,64,66 In a prospective
study of nondiabetic men, ADT significantly decreased insulin
sensitivity after 12 weeks.
63 ADT did not significantly alter
fasting plasma glucose levels, but did modestly increase
glycated hemoglobin levels.
DIABETES
The incidence of diabetes has doubled in the last 30 years
74
and is projected to rise further.
75 The National Health and
Nutrition Examination Survey (NHANES) from 1999–2002
estimated the prevalence of diabetes in the population at
6.5%, with another 2.8% undiagnosed.
76 When these percen-
tages are added to the 26.0% prevalence of impaired fasting
glucose, more than a third of the US population either has
diabetes or is at high risk for developing it.
Among 73,196 men in a SEER-Medicare database who were
age 66 or older with locoregional prostate cancer,
9 36% were
treated with a GnRH agonist and 7% underwent bilateral
orchiectomy during follow-up (median of 4.55 years). The
adjusted hazard ratio for incident diabetes was significantly
higher among the men treated with GnRH agonists during
follow-up (HR 1.44; P<0.001). A preliminary report from a
population-based study of Canadian men with prostate cancer
confirmed the association between ADT and greater incidence
of diabetes.
77
Based on the prevalence of occult diabetes in older men and
the observed association between ADT and greater incidence of
diabetes, we recommend screening and intervention to reduce
diabetes in line with guidelines from the ADA.
78 Given the
alterations in insulin sensitivity and the association of ADT
S391 Saylor et al.: Prostate Cancer Survivorship JGIMwith diabetes, we recommend testing of all men receiving long-
term ADT at baseline and within 1 year of initiation (see
Table 1). Fasting plasma glucose is the preferred diagnostic
test and should be repeated yearly while on ADT. The use of
A1C for the diagnosis of diabetes is not recommended. The
ADA recommends counseling 5–10% weight loss and at least
150 min/week of moderate physical activity to prevent or delay
diabetes in those with impaired fasting glucose (fasting glucose
100–125 mg/dl).
CARDIOVASCULAR DISEASE
Cardiovascular disease is the leading cause of death in the US
and its prevalence rises with age. Obesity, insulin resistance
and elevated triglycerides are all associated with ADT. Studies
of ADT and cardiovascular disease are mixed. One analysis of
the SEER-Medicare data demonstrated that men receiving
GnRH agonists were more likely to develop incident coronary
heart disease (HR 1.16; P<0.001), myocardial infarction (HR
1.11; P=0.03) and sudden cardiac death (HR 1.16, P=0.004).
9
Another population-based study of 23,000 men with prostate
cancer demonstrated a 20% rise in 1-year cardiovascular
morbidity.
79 A population-based observational study with
relatively short follow-up (3.9 years) and few events (61)
reported greater cardiovascular mortality in a subset of older
men who underwent prostatectomy.
80 Notably, this increase in
cardiovascular morality was not apparent in the overall study
population and traditional cardiovascular disease risk factors,
including prevalent cardiovascular disease and diabetes, were
not associated with cardiovascular mortality. A pooled analysis
of three small randomized controlled trials of men with
clinically localized prostate cancer suggested that 6 months
of ADT led to earlier onset of fatal myocardial infarction in the
subset of men at least 65 years old.
81 This article’s statistical
methods have been criticized for the low number of observed
events (16 in the control group and 18 in the ADT group).
82
In contrast, a preliminary report from a population-based
study of Canadian men with prostate cancer found no signifi-
cant association between ADT and acute myocardial infarc-
tion.
77 Secondary analyses of three large randomized controlled
trials from the Radiation Therapy Oncology Group (RTOG) of
men with locally advanced prostate cancer reported no associ-
ation between neoadjuvant/adjuvant ADT and cardiovascular
mortality.
83–85 Similarly, secondary analyses of a randomized
controlled trial from the European Organization for Research
and Treatment of Cancer (EORTC) reported no association
between ADT and cardiovascular mortality. Major strengths of
the RTOG and EORTC studies include randomized study design,
large sample size, long follow-up and a relatively large number
of events.
Given the uncertain association between ADT and myocar-
dial infarction, we recommend a standard emphasis on
primary prevention as guided by NCEP ATP III and the
American Heart Association (AHA) guidelines. Tobacco cessa-
tion and aggressive management of hypertension should be
pursued for all. Low-dose aspirin is appropriate for men with
at least 10% 10-year risk of CHD. Lifestyle interventions
should include weight control, regular physical activity, and
reduced intake of saturated fat and cholesterol. Statins are
first line for the treatment of hyperlipidemia if lifestyle inter-
ventions fail to bring LDL cholesterol to goal.
CONCLUSIONS AND RECOMMENDATIONS
For many men, prostate cancer is a chronic disease. As
prostate cancer specific mortality has fallen to low levels,
internists and oncologists commonly manage men with pros-
tate cancer for years and sometimes for decades. ADT, the
mainstay of treatment for recurrent and metastatic prostate
cancer, has a variety of recently recognized adverse metabolic
effects including osteoporosis, obesity, insulin resistance and
lipid alterations. Recently, ADT has also been associated with
greater risk for fractures, diabetes and cardiovascular disease.
Recognition and prevention of these potential treatment-
related harms are essential to promoting the health of prostate
cancer survivors.
ADT increases the incidence of clinical fractures in prostate
cancer survivors. All such men should be encouraged to take
supplemental calcium (≥1,200 mg daily) and vitamin D (800–
1,000 IU daily). We advocate the use of the online WHO/FRAX
fracture risk tool (http://www.shef.ac.uk/FRAX/index.htm)t o
estimate fracture risk in individual patients and identify
candidates for pharmacologic intervention. The results of
recently completed large phase III fracture prevention studies
(see Table 2) will help establish evidence-based guidelines for
fracture prevention for men receiving ADT.
Although insulin resistance and changes in body composi-
tion are both substantial burdens to men receiving ADT and
associated with increased risk of diabetes, effective manage-
ment strategies have not yet been established. In men and
women at high risk for diabetes in the general population, the
Diabetes Prevention Trial found that physical activity and
weight loss reduced the incidence of diabetes by 58% com-
pared with controls. This was almost twice the reduction
achieved with metformin.
86 A randomized trial of intensive
lifestyle intervention in men treated with GnRH agonists is
ongoing. This trial is designed to detect improvements in
insulin sensitivity and markers of cardiovascular disease.
Cardiovascular disease and diabetes are two of the leading
causes of non-cancer death among all patients with cancer
87
and are particular concerns among men treated with GnRH
agonists. We believe the best available management strategy is
to employ broadly accepted practice guidelines for patients in
the general population, including recommendations for man-
agement of hyperlipidemia,
70 the detection and management
of pre-diabetes and diabetes,
78 and primary and secondary
prevention of cardiovascular disease.
88
Internists work with radiation oncologists, urologists and
medical oncologists to promote the health of the growing
population of medically vulnerable older men with prostate
cancer. Survivorship research has defined many risks unique
to this population. Awareness of the recently described adverse
effects of GnRH agonists allows clinicians to educate, motivate
and manage their patients to combat these changes. We
anticipate that recently completed and ongoing trials will
further guide our efforts to reduce treatment-related morbidity.
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